January 25th 2012 | Biologics, Patient Stories, Psoriasis Cure Now, Psoriasis Research, Public policy issues, psoriatic arthritis | 4 Comments
Before 2011 becomes a distant memory, Psoriasis Cure Now felt it would be useful to highlight what we believe were the top psoriasis and psoriatic arthritis stories of 2011. The year included bad news about a promising treatment from Abbott, as well as a psoriasis sub-plot to one of the more ridiculous media sensations
READ THE FULL POST
March 2nd 2011 | Biologics, Health care system, Public policy issues, psoriatic arthritis | 1 Comment
We’re happy to see the Phil Mickelson psoriasis, psoriatic arthritis, and RA campaign launch. Go Phil! We hope he is winning again soon.
The campaign is called On Course with Phil, and you can see the site here: http://www.oncoursewithphil.com .
The campaign is owned by Amgen & Pfizer (they market the popular biologic Enbrel [etanercept]). Our only
READ THE FULL POST
February 16th 2011 | Get involved, Psoriasis Cure Now, Psoriasis Research, Public policy issues | 2 Comments
The US Government, through the National Institutes of Health (NIH), maintained in 2010 its record level of research funding for psoriasis and psoriatic arthritis. The total was $16 million, as it was in 2009. As recently as 2005 the total was just $5 million.
Progress!
Read more about research funding for psoriasis and psoriatic arthritis.
February 10th 2011 | Alternative/buyer beware/natural, Health care system, Public policy issues, Treatment | 7 Comments
Are you paying too much for nonprescription psoriasis treatments? Many psoriasis patients are paying WAY too much for 2% coal tar and other common psoriasis treatments.
Post a comment below or email us [ info@psoriasis-cure-now.org ] with your most expensive NON-prescription meds; we’re going to start calling out these overpriced products and their doctor and nonprofit
READ THE FULL POST
November 22nd 2010 | Psoriasis Videos, Public policy issues | 0 Comments
Jon Lovitz, the 1990s Saturday Night Live actor and “Yeah, that’s the ticket” guy, has been signed by Centocor Ortho Biotech to do a series of humorous videos about psoriasis. The tagline is “Are You Serious?” and the website is http://seriousaboutpsoriasis.com. Centocor Ortho Biotech markets Remicade for psoriasis and psoriatic arthritis; Stelara for psoriasis;
READ THE FULL POST
October 6th 2010 | Biologics, Health care system, Public policy issues, psoriatic arthritis | 0 Comments
In what may be a look at the future of the U.S. health care system, the National Institute for Health and Clinical Excellence (NICE) in Britain has recommended denying psoriatic arthritis patients reimbursement for the biologic Simponi (golimumab) in the country’s government-run health care system.
NICE has generated great controversy in the United States, with President
READ THE FULL POST
October 5th 2010 | Biologics, Health care system, Insurance, Public policy issues | 0 Comments
New York Governor David Patterson recently signed many new measures into law, including one that could benefit psoriasis and psoriatic arthritis patients being treated with biologics:
Among the bills signed by Governor Paterson is S.5000-B/A.8278-B, which will codify in law the currently regulatory authority of the State Insurance Department to disapprove requests from insurance carriers
READ THE FULL POST
September 20th 2010 | Get involved, Psoriasis Cure Now, Psoriasis Research, Public policy issues, psoriatic arthritis | 0 Comments
With World Psoriasis Day coming on October 29, 2010, Psoriasis Cure Now has launched the World Psoriasis Day Challenge, to nudge the day toward focusing on increasing research funding worldwide for psoriasis and psoriatic arthritis. Check it out and let us know what you think! Comments are open below….
June 30th 2009 | Biologics, Psoriasis Research, Public policy issues | 0 Comments
“Psoriasis Cure Now,” a nonprofit patient advocacy group, today applauded the Institute of Medicine (IOM) for including psoriasis and psoriatic arthritis among its Top 100 health topics meriting priority “comparative effectiveness” research, but the organization expressed concern that treatment rationing could result from the research.
The IOM included the use of biologics for treating inflammatory diseases
READ THE FULL POST
